Tenovi’s Cellular-Connected BP Monitor listed on validatebp.org after meeting rigorous clinical accuracy standards
Tenovi, a leading provider of remote monitoring solutions, today announced that the cellular-connected Tenovi Blood Pressure Monitor models (TC-BPM-L2, TC-BPM-S2, and TC-BPM-A2 / TC-BPM-M2) meet the Validated Device Listing (“VDL”) criteria (as listed on validatebp.org) for validation of clinical accuracy, based on the independent review and acceptance of documentation submitted by the manufacturer.
The listing reinforces Tenovi’s commitment to clinical accuracy and gives healthcare teams added confidence when selecting a blood pressure monitor for RPM programs.
Research shows that some home blood pressure monitors can be inaccurate by 10% to 72% compared to mercury sphygmomanometers, depending on the device and model.¹ Because of this wide variability, only a limited number of devices in the U.S. have been independently validated for clinical use.
“Earning a place on the Validated Device Listing is a rigorous process, and we are proud to offer our clients and partners a clinically validated RPM blood pressure monitor for added trust,” said Nizan Friedman, Ph.D., Founder and CEO of Tenovi. “This milestone reinforces our commitment to accuracy and reliability in patient care.”
1Hiremath, Swapnil & Sterling, Brayden & Glassman, Isaac & Ruzicka, Marcel. (2024). Abstract P317: Are Home Blood Pressure Devices Accurate? A Systematic Review of the Evidence. Hypertension. 81. 10.1161/hyp.81.suppl_1.P317.
Read the full press release on EIN Wire.
